Atogepant: Aquipta
Marketing authorisation number 69128, date marketing authorisation granted: 06/03/2024
We publish synopses from Clinical Study Reports (CSR) to supplement the public information. This provides patients and healthcare providers with the results of our clinical trials and the evidence used for the authorisation of Aquipta.
Here you can find the CSR synopses after Aquipta was granted marketing authorisation in Switzerland.
CGP-MD-01
Study indication: episodic migraine
Phase: phase 2/3
Study name:
A phase 2/3 multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of oral atogepant with multiple dosing regimens for the prevention of episodic migraine.
EudraCT number: n/a
3101-301-002
Study indication: episodic migraine
Phase: phase 3
Study name: A phase 3 multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of atogepant in patients with episodic migraine.
EudraCT number: n/a
3101-303-002
Study indication: chronic migraine
Phase: phase 3
Study name:
A phase 3 multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety and tolerability of atogepant for the prevention of chronic migraine.
EudraCT number: 2018-004337-32
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright © 2025 AbbVie Inc. North Chicago, Illinois, U.S.A.